

## Special Issue

# Frontiers in Cross-Protective Vaccines

### Message from the Guest Editors

The inclusion of cross-protective antigens is usually considered desirable when developing vaccines against different pathogens of several species and may also be important from a public health perspective. In this Special Issue, we encourage our colleagues to search within the abundant data available from all “omics” and other resources towards identifying promising cross-reactive antigens for vaccine development. Such vaccines may include single or multiple cross-reactive antigens and may help to prevent unpredictable homologous and heterologous infections. It is expected that this novel vaccine development approach will have a major impact in the context of disease prevention, while also having economic and practical advantages. We welcome your interesting research or review article covering these topics in our current Special Issue titled “Frontiers in Cross-Protective Vaccines”.

---

### Guest Editors

Prof. Dr. Maria Tempesta

Department of Veterinary Medicine, University Aldo Moro of Bari, Sp Casamassima Km 3, Valenzano, 70010 Bari, Italy

Dr. Heba Alzan

Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA

---

### Deadline for manuscript submissions

closed (31 May 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/74964](https://mdpi.com/si/74964)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).